ARCHER S, ALBERTSON N F, HARRIS L S, PIERSON A K, BIRD J G, KEATS A S, TELFORD J, PAPADOPOULOS C N
Science. 1962 Aug 17;137(3529):541-3. doi: 10.1126/science.137.3529.541.
2-Dimethylallyl- 5,9-dimethyl-2'-hydroxybenzomorphan (Win 20,228) was found to be a weak antagonist of morphine and meperidine, whereas 2-allyl-5-ethyl-2'- hydroxy-9-methyl-6,7-benzomorphan (Win 19,362) and 2-allyl-2'-hydroxy-5,9- dimethyl-6,7-benzomorphan (Win 19,631) were about three times as potent as nalorphine. Preliminary clinical trials indicate that Win 19,362 is about twice as potent as morphine as an analgesic but, like nalorphine, is capable of producing severe psychic side effects. Win 20,228 is estimated to be about half as active as morphine as an analgesic, but no bizarre psychic effects were reported at any dose tested. Studies of addiction liability with Win 20,228 in monkeys suggest that this compound will not support morphine addiction.
2-二甲基烯丙基-5,9-二甲基-2'-羟基苯并吗啡烷(Win 20,228)被发现是吗啡和哌替啶的弱拮抗剂,而2-烯丙基-5-乙基-2'-羟基-9-甲基-6,7-苯并吗啡烷(Win 19,362)和2-烯丙基-2'-羟基-5,9-二甲基-6,7-苯并吗啡烷(Win 19,631)的效力约为烯丙吗啡的三倍。初步临床试验表明,Win 19,362作为镇痛药的效力约为吗啡的两倍,但与烯丙吗啡一样,能够产生严重的精神副作用。据估计,Win 20,228作为镇痛药的活性约为吗啡的一半,但在任何测试剂量下均未报告有怪异的精神效应。用Win 20,228对猴子进行的成瘾性研究表明,该化合物不会维持吗啡成瘾。